HUTCHMED (China) Limited - American Depositary Shares (HCM)
Frequently Asked Questions About HUTCHMED (China) Limited - American Depositary Shares (HCM)
Does HUTCHMED have any partnerships or collaborations?
Yes, HUTCHMED has established various partnerships and collaborations with leading global pharmaceutical companies and research institutions. These alliances are aimed at enhancing its capabilities in drug development and commercialization, as well as accessing broader market opportunities.
How can investors learn more about HUTCHMED?
Investors can learn more about HUTCHMED by visiting the company's official website, where they can find information on its products, clinical trials, investor relations, and corporate governance. The company also provides regular updates through press releases and investor presentations to keep stakeholders informed.
How does HUTCHMED contribute to the healthcare industry?
HUTCHMED contributes to the healthcare industry by developing innovative therapeutics that address unmet medical needs, particularly in oncology and autoimmune diseases. By advancing research and promoting novel treatments, the company helps improve patient outcomes and supports the overall growth of the biopharmaceutical sector.
How does HUTCHMED ensure quality in its products?
HUTCHMED ensures the quality of its products through a comprehensive Quality Assurance (QA) program that encompasses every stage of the drug development process. This includes strict adherence to Good Manufacturing Practices (GMP), thorough testing procedures, and continuous monitoring to meet regulatory requirements and industry standards.
How does HUTCHMED support research and development?
HUTCHMED supports research and development through substantial investments in its R&D capabilities, including a dedicated team of scientists and access to state-of-the-art technology. The company collaborates with academic institutions and other organizations to enhance its drug discovery processes and clinical development efforts.
Is HUTCHMED publicly traded?
Yes, HUTCHMED (China) Limited is publicly traded. It has American Depositary Shares (ADS) listed on the NASDAQ stock exchange under the ticker symbol HCM, allowing investors to trade its shares in the United States while also being listed on the Hong Kong Stock Exchange.
What are the company's goals for the future?
HUTCHMED aims to expand its pipeline of innovative drug candidates, enhance its presence in global markets, and develop strategic partnerships to accelerate growth. The company's overarching goal is to provide transformative therapies that significantly improve the lives of patients worldwide.
What are the main therapeutic areas HUTCHMED focuses on?
HUTCHMED primarily focuses on oncology and autoimmune diseases. The company aims to address significant unmet medical needs in these areas by developing targeted therapies and novel agents, thereby contributing to improved patient outcomes and expanding treatment options.
What does HUTCHMED (China) Limited do?
HUTCHMED (China) Limited is an innovative biopharmaceutical company focused on developing proprietary drugs for the treatment of cancer and autoimmune diseases. The company is involved in the discovery, development, manufacture, and commercialization of its drug candidates, utilizing its extensive capabilities in research and development, along with partnerships in various global markets.
What is fruquintinib?
Fruquintinib is an oral small molecule inhibitor of VEGFR, designed to treat colorectal cancer. It has shown promising efficacy in clinical trials and has been approved for use in China, representing a significant advance in treatment options for patients with this type of cancer.
What is HUTCHMED's approach to patient engagement?
HUTCHMED values patient engagement and strives to incorporate patient feedback into its development processes. The company believes that understanding the patient journey and their experiences with treatments is crucial for creating effective therapies that truly meet patient needs.
What is HUTCHMED's commitment to clinical trials?
HUTCHMED is dedicated to conducting rigorous clinical trials that adhere to the highest scientific and ethical standards. The company invests heavily in clinical research to assess the safety and efficacy of its drug candidates, aiming to bring breakthrough therapies to market effectively and safely.
What is surufatinib?
Surufatinib is a novel oral medication developed by HUTCHMED that targets tumor angiogenesis and immune modulation. It has been evaluated in clinical trials for patients with neuroendocrine tumors and other solid tumors, showcasing the company's commitment to advancing treatment options for difficult-to-treat cancers.
What is the company's stance on sustainability?
HUTCHMED is committed to sustainability and social responsibility. The company actively seeks to minimize its environmental footprint while maximizing the positive impact on communities through its philanthropic initiatives. This commitment extends to ethical business practices and transparent operations.
What markets does HUTCHMED operate in?
HUTCHMED operates primarily in China, where it has a robust presence, while also expanding into international markets. The company aims to bring its innovative therapies to patients globally, especially in other key markets such as the United States and Europe.
What products has HUTCHMED developed?
HUTCHMED has developed a range of innovative products, including its cancer therapies like fruquintinib, a targeted therapy for colorectal cancer, and surufatinib, which targets both solid tumors and neuroendocrine tumors. The company continues to expand its portfolio with multiple candidates in various stages of clinical development.
Where is HUTCHMED headquartered?
HUTCHMED (China) Limited is headquartered in Hong Kong, where it maintains its central operations and coordinates its extensive research and development activities across multiple countries. The company leverages Hong Kong's strategic location to access international markets while also focusing on its primary market in China.
Who are the key executives at HUTCHMED?
HUTCHMED is led by a team of experienced executives with deep expertise in the biopharmaceutical sector. This includes the company's founder and CEO, who has extensive experience in drug development and management. The leadership team's diverse backgrounds enable HUTCHMED to pursue its strategic objectives effectively.
What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
The current price of HUTCHMED (China) Limited - American Depositary Shares is 14.27
When was HUTCHMED (China) Limited - American Depositary Shares last traded?
The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 1:48 pm EDT on April 4th, 2025
What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 12.43B
How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
HUTCHMED (China) Limited - American Depositary Shares has 871.26M shares outstanding.